EQS-News: Marinomed Biotech AG / Key word(s): Half Year Results
Marinomed Biotech AG announces results for the first half year of 2025
17.09.2025 / 13:48 CET/CEST
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Marinomed Biotech AG announces results for the first half year of 2025
• Revenues amounted to EUR 7.2 million in the first half of 2025 (H1
2024: EUR 2.4 Mio.)
• EBIT of EUR 21.0 Mio., which includes a restructuring gain
• Financing secured by the latest capital measures
Korneuburg, Österreich, September 17, 2025 - Marinomed Biotech AG
(VSE:MARI) significantly increased both revenue and earnings in the first
half of 2025. Revenue amounted to EUR 7.2 million (H1 2024: EUR 2.4
million). Operating profit (EBIT) was EUR 21.0 million (H1 2024: EUR –3.2
million), significantly influenced by other operating income of EUR 19.3
million, which includes a restructuring gain of EUR 18.9 million. Cash
flow from operating activities was slightly negative at EUR –0.2 million.
Cash and cash equivalents as of June 30, 2025, amounted to EUR 1.5
million, compared to EUR 0.9 million in the previous year. Balance sheet
total decreased to EUR 7.6 million (December 31, 2024: EUR 8.2 million).
"The sale of the Carragelose business has significantly strengthened our
financial base. We see this as an important intermediate step in advancing
our pipeline of Marinosolv projects and building the foundation for
sustainable growth. With the targeted approval of Budesolv, we have made
significant operational progress in recent months. We are well on track.
Our operational progress is also reflected in the development of our key
figures—cash flow from operating activities has improved, however, still
slightly negative. The recently announced capital measures have further
strengthened our financial base," added Gabriele Ram, CFO of Marinomed.
"The planned convertible bond in the amount of EUR 2.5 million, as well as
the capital increase of EUR 1.1 million announced yesterday not only
strengthen our negotiating position with potential licensing partners for
our development projects Budesolv and Tacrosolv, but also enable us to
advance more rapidly on the operational side. Marinomed's current
financial planning does not include any further capital measures,“
according to Andreas Grassauer, CEO of Marinomed.”
Selected financial figures for H1 2025
All amounts in kEUR H1 2025 H1 2024
Revenues 7,178.1 2,418.7
Operating result (EBIT) 20,971.8 -3,182.4
R&D Expenses -1,400.0 -2,386.9
Cash flow utilized by operating activities -214.5 -1,828.9
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline. The Company develops innovative
patent-protected products based on the Marinosolv® platform. The
Marinosolv® technology improves the solubility and bioavailability of
hardly soluble compounds and is used to develop new therapeutics for
autoreactive immune disorders. The Company is headquartered in Korneuburg,
Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
further information, please visit: https://www.marinomed.com:
(1)https://www.marinomed.com.
For further inquiries contact:
Marinomed Biotech AG
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: (2)pr@marinomed.com
E-Mail: (3)ir@marinomed.com
Disclaimer
This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are
subject to risks, uncertainties and assumptions that could cause actual
results, performance or events to differ materially from those described
in, or expressed or implied by, such statements. The current views,
expectations and projections of the management of Marinomed Biotech AG may
be identified by the context of such statements or words such as
“anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
and “target”. Forwardlooking statements are only valid as of the date they
are made and Marinomed Biotech AG does not assume any obligation to
update, review or revise any forward-looking statements contained in this
press release whether as a result of new information, future developments
or otherwise.
══════════════════════════════════════════════════════════════════════════
17.09.2025 CET/CEST This Corporate News was distributed by EQS Group.
www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 2199130
End of News EQS News Service
2199130 17.09.2025 CET/CEST
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2199130&application_name=news&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf
References
Visible links
1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=2199130&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
2. mailto:pr@marinomed.com
3. mailto:ir@marinomed.com
OTS original text press release with the exclusive in terms of content of the sender – www.ots.at |